Table 2.
Symptoms of the eyes and airways comparing different genotypes among TDI-exposed and non-exposed workers.a
| Geno-type | Symptoms | ||||||
| Yes (N) | No (N) | ORb | 95% CI | Pc* | |||
| EYES | |||||||
| Exposed | NAT1 | IM+S | 33 | 53 | 1.0 | - | 0.067 |
| R | 23 | 17 | 2.2 | 1.0–4.9 | |||
| Unexposed | NAT1 | IM+S | 19 | 60 | 1.0 | - | |
| R | 6 | 27 | 0.63 | 0.22–1.9 | |||
| Exposed | SULT1A1 R213H | GG | 27 | 14 | 1.0 | - | 0.19 |
| AG+AA | 29 | 56 | 0.22 | 0.096–0.52 | |||
| Unexposed | SULT1A1 R213H | GG | 13 | 31 | 1.0 | ||
| AG+AA | 12 | 56 | 0.56 | 0.22–1.4 | |||
| Exposed | TNF-308 | GG | 36 | 44 | 1.0 | - | 0.11 |
| GA+AA | 17 | 19 | 1.0 | 0.47–2.4 | |||
| Unexposed | TNF-308 | GG | 11 | 57 | 1.0 | - | |
| GA+AA | 14 | 25 | 2.6 | 1.0–7.0 | |||
| WHEEZE | |||||||
| Exposed | CYP1A1*2B | I/I | 34 | 87 | 1.0 | - | 0.061 |
| I/V | 5 | 1 | 14 | 1.5–130 | |||
| Unexposed | CYP1A1*2B | I/I | 23 | 82 | 1.0 | - | |
| I/V | 1 | 6 | 0.83 | 0.090–7.7 | |||
| Exposed | SULT1A1 R213H | GG | 17 | 25 | 1.0 | - | 0.58 |
| AG+AA | 22 | 63 | 0.52 | 0.22–1.2 | |||
| Unexposed | SULT1A1 R213H | GG | 14 | 30 | 1.0 | - | |
| AG+AA | 10 | 58 | 0.38 | 0.15–0.99 | |||
| Exposed | CCL5 -403 | GG | 19 | 64 | 1.0 | - | 0.42 |
| AG+AA | 20 | 21 | 3.1 | 1.3–7.1 | |||
| Unexposed | CCL5 -403 | GG | 13 | 58 | 1.0 | - | |
| AG+AA | 10 | 29 | 1.8 | 0.68–5.0 | |||
| Exposed | TNF-308 | GG | 29 | 52 | 1.0 | - | 0.043 |
| GA+AA | 7 | 30 | 0.37 | 0.14–0.99 | |||
| Unexposed | TNF-308 | GG | 13 | 55 | 1.0 | - | |
| GA+AA | 10 | 29 | 1.3 | 0.46–3.4 | |||
| DRY COUGH | |||||||
| Exposed | HLADQB1*05 | Absent | 20 | 62 | 1.0 | - | 0.047 |
| Present | 18 | 20 | 2.7 | 1.2–6.3 | |||
| Unexposed | HLADQB1*05 | Absent | 12 | 74 | 1.0 | - | |
| Present | 1 | 23 | 0.27 | 0.031–2.2 | |||
| Exposed | TNF-308 | GG | 30 | 50 | 1.0 | - | 0.023 |
| GA+AA | 7 | 28 | 0.43 | 0.17–1.1 | |||
| Unexposed | TNF-308 | GG | 6 | 62 | 1.0 | - | |
| GA+AA | 7 | 32 | 2.2 | 0.66–7.3 | |||
| COUGH WITH MUCUS | |||||||
| Exposed | GSTM1 | Present | 19 | 45 | 1.0 | - | 0.13 |
| Absent | 24 | 39 | 1.4 | 0.66–3.0 | |||
| Unexposed | GSTM1 | Present | 8 | 55 | 1.0 | - | |
| Absent | 18 | 31 | 3.5 | 1.3–9.4 | |||
| Exposed | GSTM3 | AA | 29 | 61 | 1.0 | - | 0.028 |
| AB+BB | 14 | 23 | 1.2 | 0.52–2.7 | |||
| Unexposed | GSTM3 | AA | 23 | 53 | 1.0 | - | |
| AB+BB | 3 | 33 | 0.22 | 0.059–0.81 | |||
| Exposed | GSTP1*105 | I/I | 26 | 41 | 1.0 | - | 0.019 |
| I/V+V/V | 17 | 43 | 0.66 | 0.32–1.4 | |||
| Unexposed | GSTP1*105 | I/I | 8 | 48 | 1.0 | - | |
| I/V+V/V | 18 | 38 | 3.0 | 1.1–8.0 | |||
| Exposed | CCL5 -403 | GG | 22 | 59 | 1.0 | - | 0.079 |
| AG+AA | 21 | 20 | 2.9 | 1.3–6.5 | |||
| Unexposed | CCL5 -403 | GG | 17 | 54 | 1.0 | - | |
| AG+AA | 8 | 31 | 0.86 | 0.32–2.3 | |||
| NOSE BLEED | |||||||
| Exposed | MPO | GG | 25 | 65 | 1.0 | - | 0.018 |
| AG+AA | 3 | 30 | 0.21 | 0.056–0.94 | |||
| Unexposed | MPO | GG | 3 | 70 | 1.0 | - | |
| AG+AA | 4 | 35 | 2.9 | 0.58–14 | |||
a Adjusted effect estimates (for sex, age, atopy, and smoking) are presented as odds ratios (OR) and 95% confidence intervals. Statistically significant results are presented in bold.
bAll results that reached statistical significance with respect to genotype-associated risk in either exposure-strata, or in the analysis of interaction between genotype and exposure status, are presented.
cAnalysis of interaction between exposure and genotype was performed in a separate model using logistic regression with interaction term. P-values regarding interaction between exposure and genotype are indicated by P*.